A randomized trial (Irish clinical oncology research group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer

What Was Tested

This randomized controlled trial paper looks at Triptorelin.

To examine the long-term outcomes of a randomized trial comparing short (4 months; Arm 1) and long (8 months; Arm 2) neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer.

Who Took Part

According to the abstract, 2001, patients were involved.

The age groups tagged for this paper are middle-aged adults and older adults, men only.

Between 1997 and 2001, 276 patients were enrolled and the data from 261 were analyzed.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Triptorelin and who got the comparison, which limits bias.

The stratification risk factors were prostate-specific antigen level >20 ng/mL, Gleason score≥7, and Stage T3 or more.

The intermediate-risk stratum had one factor and the high-risk stratum had two or more.

Staging was done from the bone scan and computed tomography findings.

The primary endpoint was biochemical failure-free survival.

What Was Measured

Topics PubMed links to this paper include Adenocarcinoma, Androgen Antagonists, Antineoplastic Agents, Hormonal, Disease-Free Survival, Flutamide, Neoadjuvant Therapy and Neoplasm Staging.

What This Means in Plain Language

The paper is a randomized study of Triptorelin in 2001, patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2011 (International journal of radiation oncology, biology, physics), a journal based in United States.

More context: the Triptorelin compound page.